Press Releases

Date Title and Summary Additional Formats
Toggle Summary Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf, iPSC-derived NK Cells First Patients Treated with FT516, the First-ever Engineered iPSC-derived Cellular Immunotherapy, for AML Read All » View HTML
Toggle Summary SAN DIEGO , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary SAN DIEGO , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today its participation in the following upcoming investor Read All » View HTML
Toggle Summary FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with High-affinity, Non-cleavable CD16 Enhance the Efficacy of Antibody Therapy SAN DIEGO Read All » View HTML
Toggle Summary FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Read All » View HTML
Toggle Summary FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of Lymphoma Combination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical Lymphoma Model Company Plans to Initiate Enrollment of First-in-human Clinical Read All » View HTML
Toggle Summary No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid Tumors Favorable Read All » View HTML
Toggle Summary SAN DIEGO , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All » View HTML
Toggle Summary SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary FT596 Selected by ASH for Feature at “CAR-T and Beyond” P ress Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event at ASH on December 6 SAN DIEGO , Nov. Read All » View HTML
Toggle Summary First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab Received FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen Targeted CAR NK Cell Product Candidate Opened State-of-the-art cGMP Read All » View HTML
Toggle Summary SAN DIEGO , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary State-of-the-Art Facility Designed to use Clonal Master iPSC Lines as Renewable Cell Source for Manufacture of Off-the-Shelf Product Pipeline   SAN DIEGO , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All » View HTML
Toggle Summary SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”)  (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All » View HTML
Toggle Summary SAN DIEGO , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.